CClinicalTrials.gg
CompletedNCT04271085iLIVEUpdated Mar 11, 2025

Living Well, Dying Well. a Research Programme to Support Living Until the End

An observational study in Terminal Care, sponsored by Erasmus Medical Center. Completed at 11 sites in 11 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-03-11.

Sponsored by Erasmus Medical Center · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
1,500
Ages
18 Years and older
Sex
All
01

Study summary

The iLIVE project involves a cohort study in which patients with an estimated life expectancy of six months or less are followed until they die. In total, the investigators will include 2200 patients in 11 countries, i.e. 200 per country. The primary outcome for the cohort study is a descriptive assessment of the concerns, expectations and preferences around dying and end-of-life care of patients and their relatives, in different settings and cultures..

Read the detailed description

Rationale: In the EU about 4 million people yearly die from a chronic illness. Many of these people die in pain or distress. Care for dying patients and their close relatives is often suboptimal.

Objective: To contribute to high-quality personalized care at the end of life by:

  1. Providing in-depth understanding of the concerns, expectations and preferences of patients in the last phase of life and their relatives
  2. Understanding the cultural, gender, age, healthcare -related and socio-economic variance in these concerns expectations and preferences Study design: The iLIVE project involves a cohort study in which patients with an estimated life expectancy of six months or less are followed until they die. In total, the investigators will include 2200 patients in 11 countries, i.e. 200 per country. Participants are requested to also involve a close relative. Both patients and relatives are asked to fill in a questionnaire, at baseline and after four weeks. If patients die during the study, the relative is asked to fill in a post-bereavement questionnaire. Medical files are studied to assess health care use in the last days of life.

Main study endpoints: The primary outcome for the cohort study is a descriptive assessment of patients' concerns, expectations and preferences around dying and end-of-life care, at baseline and after one month of follow-up.

Potential risks and benefits associated with participation: The study population concerns vulnerable people who may experience fluctuating symptoms and levels of suffering across their disease trajectory. The investigators acknowledge the risk of overburdening or stigmatizing participants. If patients feel burdened by participating in the study, they are encouraged to indicate that. The investigators will develop a protocol for researchers and interviewers to address such situations.

02

Conditions studied

  • Terminal Care

Keywords

  • Patients in the last phase of life
03

In context

Lead sponsor

Erasmus Medical Center is the lead sponsor of 466 studies on the registry; 179 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

All competent adult patients with an estimated life expectancy of six months or less are eligible, regardless of their diagnosis, gender or age, or place of residence, and their relatives

Eligibility criteria

Inclusion Criteria patients:

  • The patient is aware that recovering from his/her disease is unlikely, to be assessed by the attending physician
  • The attending physician would not be surprised if the patient were to die within 6 months
  • If the physician is uncertain about the surprise question, the patient is eligible if presenting with at least one SPICT indicator:

General SPICT indicators:

  • Unplanned hospital admission
  • Performance status is poor or deteriorating, with limited reversibility (eg stays in bed or in a chair for more than half the day)
  • Depends on others for care due to increasing physical and/or mental health problems; person's carer needs more help and support
  • Progressive weight loss; remains underweight; low muscle mass
  • Persistent symptoms despite optimal treatment of underlying condition(s)
  • Person (or family) asks for palliative care; chooses to reduce, stop or not have treatment; or wishes to focus on quality of life

Disease-specific SPICT indicators:

Cancer:

  • Functional ability deteriorating due to progressive cancer
  • Too frail for cancer treatment or treatment is for symptom control

Neurological disease:

  • Progressive deterioration in physical and/or cognitive function despite optimal therapy
  • Speech problems with increasing difficulty communicating and/or progressive difficulty with swallowing
  • Recurrent aspiration pneumonia; breathless or respiratory failure
  • Persistent paralysis after stroke with significant loss of function and ongoing disability

Heart/vascular disease:

  • Heart failure or extensive, untreatable coronary artery disease; with breathlessness or chest pain at rest or on minimal effort
  • Severe, inoperable peripheral vascular disease

Respiratory disease:

  • Severe, chronic lung disease; with breathlessness at rest or on minimal effort between exacerbations
  • Persistent hypoxia needing long term oxygen therapy
  • Has needed ventilation for respiratory failure or ventilation is contraindicated

Kidney disease:

  • Stage 4 or 5 chronic kidney disease (eGFR \< 30ml/min) with deteriorating health
  • Kidney failure complicating other life limiting conditions or treatments
  • Stopping or not starting dialysis

Liver disease:

  • Cirrhosis with one or more complications in the past year: diuretic resistant ascites; hepatic encephalopathy; hepatorenal syndrome; bacterial peritonitis; or recurrent variceal bleeds
  • Liver transplant is not possible

Dementia/ frailty:

  • Unable to dress, walk or eat without help
  • Eating and drinking less, difficulty with swallowing
  • Urinary and faecal incontinence
  • Not able to communicate by speaking; little social interaction
  • Frequent falls; fractured femur
  • Recurrent febrile episodes or infections, aspiration pneumonia

Other conditions:

o Deteriorating and at risk of dying with other conditions or complications that are not reversible; any treatment available will have a poor outcome

Exclusion Criteria patients:

  • The patient is incapable of filling in a questionnaire in the country's main language or in English (patients may be supported by relatives when filling in the questionnaire)
  • The patient is incapable of providing informed consent to participate in the study, to be assessed by the attending physician

Inclusion Criteria relatives:

  • Family, friend or other close relative of the patient
  • 18 years or older
  • The relative is aware that it is unlikely that that patient will recover from his/her disease

Exclusion Criteria relatives:

  • The relative is incapable of filling in a questionnaire in the country's main language or in English
  • The relative is incapable of providing informed consent to participate in the study
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
1,500 participants (actual)
Patient registry
No

Groups and cohorts

  • Patients in the last phase of life

    Patients in the last phase of life and their families

    Other: Observational study

Interventions

  • OtherObservational study

    No intervention involved

06

What researchers measure

Primary outcomes

  1. Concerns, expectations and preferences around dying and end-of-life care (descriptive assessment of prevalence)

    Self developed questions, adapted from the Serious Illness Conversation Guide and the AEOLI questionnaire.

    Time frame: Baseline

  2. Concerns, expectations and preferences around dying and end-of-life care (descriptive assessment of prevalence)

    Self developed questions, which were inspired by the Serious Illness Conversation Guide and the AEOLI questionnaire.

    Time frame: One month of follow-up

Secondary outcomes

  1. Edmonton Symptom Assessment Scale (range 0-10, with higher score meaning worse outcome)

    Symptoms

    Time frame: At baseline and after one month of follow-up

  2. European Organisation for Research and Treatment of Cancer Quality of Life C15-Palliative Care questionnaire, quality of life item (range 1-7, with higher score indicating better outcome)

    Quality of life

    Time frame: At baseline and after one month of follow-up

  3. EuroQol-5d questionnaire (range 1-5 per item, with higher score indicating worse outcome)

    Quality of life

    Time frame: At baseline and after one month of follow-up

  4. ICECAP Supportive Care Measure (range 1-4 per item, with higher score indicating worse outcome)

    Experience of support

    Time frame: At baseline and after one month of follow-up

  5. Use of medical interventions (hospitalisation, medication, surgery, other interventions)

    Retrospective assessment for patients who die during follow-up of medical interventions in the last week of patients' life, using a self-developed checklist

    Time frame: One week

  6. Bereaved relatives' experiences

    International Care of the dying questionnaire (descriptive), Hogan Grief Reaction Checklist (despair (13 items) and personal growth (12 items) scales, range 1-5 per item)

    Time frame: 8-10 weeks post-bereavement

07

Study locations

11 sites
  • Pallium Latinoamérica
    Buenos Aires, Argentina
  • University Hospital Cologne
    Cologne, Germany
  • Landspitali National University Hospital of Iceland
    Reykjavík, Iceland
  • Agnes van der Heide
    Rotterdam, 3000 CA, Netherlands
  • Arohanui Hospice Service
    Palmerston North, New Zealand
  • Haukeland University Hospital
    Bergen, Norway
  • University Clinic for Respiratory and Allergic Diseases Golnik
    Ljubljana, Slovenia
  • Centro de Cuidados Paliativos Cudeca
    Málaga, Spain
  • Skåne University Hospital
    Lund, Sweden
  • Bern University Hospital
    Bern, Switzerland
  • University of Liverpool
    Liverpool, United Kingdom
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 11, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04271085
Lead sponsor
Erasmus Medical Center
Collaborators
University of Liverpool, Klinikum der Universität Köln, Lund University, The University Clinic of Pulmonary and Allergic Diseases Golnik, University of Bern, Cudeca Hospice Foundation, Helse-Bergen HF, Landspitali University Hospital, Pallium Latinoamérica N.G.O, University of Humanistic Studies, Medical University of Vienna, Arohanui Hospice Service Trust
Responsible party
Agnes van der Heide (Professor, Erasmus Medical Center) — Principal investigator
First posted
Feb 17, 2020
Start date
Sep 1, 2020
Primary completion
Jul 31, 2023
Completion
Jul 31, 2023
Last update
Mar 11, 2025

Study contacts

Agnes van der Heide, PhD
principal investigator · Erasmus Medical Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion